Business Description

Guardant Health Inc. is a precision oncology company that specializes in liquid biopsy tests for cancer detection, monitoring, and treatment. The company’s flagship product, Guardant360, drives revenue through diagnostic testing and strategic collaborations with healthcare providers and pharmaceutical firms. Led by CEO Helmy Eltoukhy, Guardant Health has established a competitive edge in genomic profiling within the molecular diagnostics market. It is now focused on expanding its product portfolio and global reach despite facing regulatory and market challenges.

Everything on Guardant Health Inc.

Revenue (FY2025) $982M
YoY growth +32.9%
Operating margin -44.5%
Direction Expanding
Gross margin 64.5%
Net margin -42.4%

Earnings Transcripts

View all transcripts ↗

Leadership & board

View leadership ↗
Helmy Eltoukhy — Chairperson and Co-Chief Executive Officer View full profile ↗ AmirAli Talasaz — Director and Co-Chief Executive Officer View full profile ↗ Ian Clark — Lead Independent Director View full profile ↗ Alex M. Azar II — Director View full profile ↗ Vijaya Gadde — Director View full profile ↗ Manuel Hidalgo Medina — Director View full profile ↗ Meghan Joyce — Director View full profile ↗ Steve Krognes — Director View full profile ↗ Roberto Mignone — Director View full profile ↗ Myrtle Potter — Director View full profile ↗ Musa Tariq — Director View full profile ↗ Michael Bell — Chief Financial Officer View full profile ↗ Darya Chudova — Chief Technology Officer View full profile ↗ Craig Eagle — Chief Medical Officer View full profile ↗ Christopher Freeman — Chief Commercial Officer View full profile ↗ Kumud Kalia — Chief Information Officer View full profile ↗ Terilyn Juarez Monroe — Chief People Officer View full profile ↗ John Saia — Chief Legal Officer and Corporate Secretary View full profile ↗

Share Repurchase Program

Latest FY repurchased
$45.0 million

Named Competitors

Bio-Reference Laboratories, Inc.Laboratory Corporation of AmericaQuest Diagnostics, Inc.

Customer Concentration

One customer (Customer B) accounted for 28% of revenue in 2025 (29% in 2024 and 31% in 2023), and revenue attributable to Medicare accounted for more than 10% of total revenue in each of 2025, 2024 and 2023.

Recent SEC Filings

2026-05-07 Reported quarterly results View filing ↗
2026-04-27 Leadership change (directors/officers) View filing ↗
2026-02-19 Reported quarterly results View filing ↗
2026-01-12 Reported quarterly results (+1 more) View filing ↗
2025-11-07 Entered a material agreement (+3 more) View filing ↗
2025-10-29 Reported quarterly results View filing ↗
2025-09-24 Regulation FD disclosure View filing ↗
2025-09-15 Leadership change (directors/officers) View filing ↗
2025-07-30 Reported quarterly results View filing ↗
2025-06-20 Shareholder vote results View filing ↗
2025-04-30 Reported quarterly results View filing ↗
2025-04-09 Entered a material agreement (+1 more) View filing ↗

More Companies

See how Top Bucket AI works for your firm

Request Demo
Top Bucket AI Research

Stay ahead of private markets

Research and market intelligence for private-markets professionals.

✓

You're subscribed.

Thanks for signing up.